MedTrace Logo

Early Detection of GEnetic Risk (EDGE)

NCT04746794 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20184

Last updated 2024-10-09

Study results available
· View outcomes & findings →

Summary

The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A "previvor" plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.

Conditions

  • Genetic Predisposition

Interventions

BEHAVIORAL

Population-level screening

The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A "previvor" plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.

Sponsors & Collaborators

Principal Investigators

  • Elizabeth M Swisher, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-25
Primary Completion
2023-05-31
Completion
2023-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746794 on ClinicalTrials.gov